Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03685045 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings

Study acronym: ETHOS II
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jan 30, 2025 to Dec 31, 2026
    • Study sites: 29 to 32
    • Study completion date: Jan 30, 2025 to Dec 31, 2028
    v6
  2. Enrollment target: 1500 to 6000
    • Study sites: 8 to 29
    • Eligibility criteria expanded, about 5 words
    v5
  3. Primary and study completion dates: Jan 30, 2022 to Jan 30, 2025v4
  4. 2 versions Re-verified since Nov 19, 2019, no change to tracked fieldsv2-v3
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for subsequent establishment of HCV screening and treatment programs in drug treatment clinics and NSPs across NSW and nationally.
Trial Details
NCT Number NCT03685045
Lead Sponsor Kirby Institute
Collaborators: National Health and Medical Research Council, Australia
Conditions
(from sponsor)		 Hepatitis C
Related terms Hepatitis C
Enrollment 6,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov